Waypoint Bio
Last reviewed
Jun 3, 2026
Sources
8 citations
Review status
Source-backed
Revision
v1 · 1,552 words
Improve this article
Add missing citations, update stale details, or suggest a clearer explanation.
Suggest edit
CtrlK
Last reviewed
Jun 3, 2026
Sources
8 citations
Review status
Source-backed
Revision
v1 · 1,552 words
Add missing citations, update stale details, or suggest a clearer explanation.
Waypoint Bio is an AI-native biotechnology company based in New York City that designs cell therapies for solid tumors by combining spatial biology with machine learning and in vivo pooled screening. The company is best known for an experimental platform that screens thousands of CAR-T cell-therapy designs inside living tumor models at once, then uses computer vision and spatial imaging to read out how each design behaves at single-cell resolution. In June 2026 Waypoint announced a $20 million Series A round led by Amplify Partners, with the money earmarked to push its lead program toward a first human trial.[1][2]
Waypoint sits in the broader AI drug discovery wave, but its pitch is narrower than most: rather than predicting small molecules or protein structures, it treats engineered immune cells as the thing to be optimized and tries to learn the design rules empirically, from data generated inside the tumor microenvironment itself.[2][6]
CAR-T therapies have transformed the treatment of some blood cancers, but they have largely failed against solid tumors. The reasons are tangled together. Solid tumors hide their target antigens unevenly, they recruit suppressive cells, and the physical environment inside the tumor exhausts engineered T cells before they can do their job. Designing a CAR-T cell that can survive and stay active in that setting means tuning many components at once: the antigen-binding domain, signaling and costimulatory modules, and various genetic payloads that change how the cell behaves. The combinatorial space is enormous, and conventional development tests candidates a few at a time.[2][6]
Waypoint's answer is in vivo spatial pooled screening. The company introduces a large library of cell-therapy designs into an animal tumor model simultaneously, lets them play out against a real tumor, and then images the tissue to see what happened. Spatial profiling captures hundreds of phenotypes at the single-cell level and records where each cell sits relative to the tumor, so the readout is not just "did the design work" but "which designs reached the tumor, persisted, and stayed functional, and why."[2][3] The company describes this as compressing years of sequential experiments into a single experiment, with deep phenotyping across thousands of designs at once.[3]
That experimental data then feeds machine-learning models. According to Amplify Partners, Waypoint built an AI system it calls Wayfinder that ingests the company's proprietary screening data, clinical samples, and the scientific literature to generate new therapeutic design hypotheses, including designs that, in Amplify's framing, "surprise and intrigue world experts."[6] The loop is meant to be self-reinforcing: screens generate data, models propose new designs, and the next round of screening tests them.
Waypoint Bio was co-founded in 2021 by Xinchen Wang, who serves as chief executive, and David Phizicky, the chief scientific officer. The two met as PhD students and roommates at the Massachusetts Institute of Technology.[4][5] Wang did his doctoral work at MIT and the Broad Institute on computational biology, genomics, and new genomics technologies, then a postdoc at Columbia University on human genetics; he holds a bachelor's degree from the University of Toronto.[4] Phizicky's background is in molecular biology, the wet-lab side of the partnership. Wang has described the pairing as complementary dry-lab and wet-lab expertise built around a shared interest in using AI, automation, and spatial biology for drug discovery.[4][5]
The company did not start where it is now. In a 2026 interview, Wang said Waypoint initially pursued human-genetics-driven target discovery, then pivoted in early 2022 toward optimizing solid-tumor cell-therapy designs with spatial biology.[5] He has been candid about the bar he thinks a real platform has to clear, arguing that a techbio platform needs to be roughly ten times better than existing approaches rather than incrementally better, and that "more or fancier features don't matter, only what new solutions they enable." The point of the platform, in his telling, is to develop drug candidates with lower failure rates or at lower cost.[5]
Waypoint first emerged publicly in June 2024, launching with $14.5 million in seed financing led by Hummingbird Ventures, with participation from other backers including Recode Ventures and pre-seed lead Fifty Years.[7][8] At launch the company framed its technology as in vivo spatial pooled screening for drug discovery, with an early focus on cell therapies for solid tumors.[7] It is headquartered at 430 East 29th Street in Manhattan, part of a cluster of New York life-sciences space, and signed a lab lease as it expanded.[3]
The platform rests on three capabilities that Waypoint and its investors describe as interlocking. The first is the pooled screen run inside a living tumor, which lets the company test many designs against the actual biology they will face rather than in a dish. The second is spatial profiling and computer vision, which turn the resulting tissue into quantitative, single-cell, location-aware data instead of the coarse two-dimensional readouts of older assays. Amplify Partners called the combination "a superpower" for cell-therapy design.[6] The third is the AI layer that learns from that data and proposes new candidates.[2][6]
A practical piece of the technology is delivery. Waypoint pairs its CAR-T designs with proprietary next-generation lentiviral vectors aimed at improving in vivo delivery, which matters for the in vivo CAR-T approach the company is pursuing.[1][2] In vivo CAR-T, in which the engineering happens inside the patient rather than through a lengthy manufacturing step outside the body, is one of the more closely watched directions in the field because it could lower the cost and complexity that have limited cell therapy's reach.
Waypoint's lead program is WAY-103, aimed at gastric and pancreatic solid tumors. The company reports that WAY-103 showed more than 15-fold greater potency in animal models than multiple clinical benchmarks, alongside reduced on-target, off-tumor toxicity.[1][2] A second program, WAY-200, targets colorectal cancer and is moving toward clinical development.[2] These are preclinical results, and animal-model potency does not always translate to patients, a caveat that applies to essentially every early-stage cell-therapy claim.
On June 1, 2026, Waypoint announced a $20 million Series A led by Amplify Partners. Elliot Hershberg, a partner at Amplify, joined the board of directors. Other investors in the round included General Catalyst, Lux Capital, Mitsui Global Investments, and Time BioVentures, alongside existing investor Hummingbird Ventures.[1][2] Amplify framed the bet as backing technical founders who can use new tools, pooled screening, spatial biology, and AI, to extend CAR-T beyond blood cancers into solid tumors and other diseases.[6]
The financing came with two notable hires. Patrick Kaifosh joined as chief technology officer; he had previously co-founded the neural-interface startup CTRL-Labs and served as a senior director at Meta Reality Labs after Meta acquired the company.[1][2] Kristen Hege, formerly senior vice president of early clinical development in hematology, oncology, and cell therapy at Bristol-Myers Squibb, joined the scientific advisory board.[2] Counting the 2024 seed, the Series A brings Waypoint's total disclosed funding to roughly $35 million.[1][7]
Waypoint said the round would fund the advancement of WAY-103 into an investigator-initiated clinical trial expected to begin in late 2026, with clinical entry planned in China, and would support expansion of its AI and spatial-biology platform and the buildout of its clinical-development team.[1][2] Running the first trial in China is a route a number of cell-therapy developers have taken to reach patients and generate clinical data more quickly.
Waypoint is one entry in a fast-growing set of companies trying to fold AI into the design of therapies rather than just the analysis of existing data. Much of the attention in AI for biology has gone to structure prediction and small-molecule generation, areas reshaped by tools like AlphaFold. Cell therapy is a harder target for pure computation because the relevant biology, how an engineered cell behaves inside a hostile tumor, is not well captured by sequence or structure alone. Waypoint's wager is that the missing ingredient is data: large, spatially resolved, in vivo datasets that let models learn design rules empirically instead of from first principles.[5][6]
Whether the approach pays off will be decided in the clinic, not the lab, and the company is still some distance from human results. What makes Waypoint worth watching is less any single claim than the shape of the loop it is building, where the screening platform and the AI models are meant to improve each other over time. If that works, it is a template other cell-therapy developers may copy. If it does not, it joins a long list of platforms that looked elegant on paper.